Author:
Yardley Denise A.,Noguchi Shinzaburo,Pritchard Kathleen I.,Burris Howard A.,Baselga José,Gnant Michael,Hortobagyi Gabriel N.,Campone Mario,Pistilli Barbara,Piccart Martine,Melichar Bohuslav,Petrakova Katarina,Arena Francis P.,Erdkamp Frans,Harb Wael A.,Feng Wentao,Cahana Ayelet,Taran Tetiana,Lebwohl David,Rugo Hope S.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference27 articles.
1. Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012;26(8):688–94, 696.
2. National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in oncology: breast cancer, Version 2.2011.
http://www.nccn.org/patients/guidelines/breast/index.html
(accessed October 7, 2013).
3. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28(23):3784–96.
4. Cardoso F, Costa A, Norton L, et al. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012;21(3):242–52.
5. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11(4):643–58.